A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer

Liu, B; Liu, Lei; Ran, Jianmin; Xie, Ning; Li, J.; Xiao, Huawu; Xiang, Yang; Tian, Chushun; Wu, Hui; Lu, Jun; Gao, Jin-Hua; Hu, Xuming; Cao, Min; Shui, Z.; Hu, Zhilan; Ouyang, Qi

doi:10.1016/j.esmoop.2023.101563

Cited by 6 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 A phase II study aimed to evaluate the efficacy and safety of eribulin plus anlotinib in patients with ABC; the mPFS of the experimental group and the control group was 5.1 versus 3.5 months, respectively (HR = 0.56, 95% CI: 0.32-0.98). 40 In our study, 88 patients received eribulin combination therapy, and the mPFS of the eribulin monotherapy and combination therapy was 4.0 and 5.0 months, respectively (Figure 2F). Multivariate Cox regression analysis found that eribulin combination therapy is a predictor of better specific PFS.…”

Section: Discussionmentioning

confidence: 58%

“…Based on this study, a phase III study evaluating the triple combination of eribulin, pertuzumab, and trastuzumab in patients with Her2(+) ABC has been carried out 21 . A phase II study aimed to evaluate the efficacy and safety of eribulin plus anlotinib in patients with ABC; the mPFS of the experimental group and the control group was 5.1 versus 3.5 months, respectively (HR = 0.56, 95% CI: 0.32–0.98) 40 . In our study, 88 patients received eribulin combination therapy, and the mPFS of the eribulin monotherapy and combination therapy was 4.0 and 5.0 months, respectively (Figure 2F).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes

Chen,

Yan,

Luo

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundThis prospective real‐world study aimed to assess the efficacy and safety of eribulin in the clinical practice against advanced breast cancer (ABC) in China.Patients and MethodsIn this study, eligible patients with inoperable locally advanced or metastatic breast cancer who had experienced prior neo−/adjuvant or failed the palliative treatment with anthracycline/taxanes were included. Eribulin (1.4 mg/m2) was infused intravenously on Day 1 and Day 8 every 3 weeks until disease progression or intolerable toxicity occurred. The progression‐free survival (PFS), overall response rate (ORR), disease control rate (DCR), and safety of the treatment were assessed.ResultsOne hundred and thirty‐four patients were enrolled. The median PFS (mPFS) was 4.3 months (95% CI: 0.3–15.4). The ORR and DCR was 32.1% and 79.1%, respectively. The mPFS of patients who received eribulin as first‐ or second‐line treatment was significantly better than those who received eribulin as ≥3‐line treatment (6.9 months [95% CI: 3.2–8.8] vs. 4.0 months [95% CI: 3.4–4.6], p = 0.006). The mPFS of patients with triple‐negative, HER2‐positive, and HER2(−)/HR(+) was 3.4 (95% CI: 2.7–4.1), 6.2 (95% CI: 2.3–10.1) and 5.0 months (95% CI: 4.1–5.9), respectively. HER2(+) patients had significantly longer PFS than TNBC patients (p = 0.022). Patients received combination therapy had a significantly longer mPFS than those who received eribulin monotherapy (5.0 months [95% CI 3.6–6.3] vs. 4.0 months [95% CI: 3.3–4.7] [p = 0.016]). Multivariate analysis revealed that MBC patients with a molecular typing of non‐TNBC receiving eribulin as ≤2‐line therapy and combination therapy had a low risk of disease progression. Neutropenia (33.58%), leukopenia (11.94%), and thrombocytopenia (4.48%) were the most common treatment‐related adverse events.ConclusionEribulin demonstrated effective clinical activity and a favorable tolerability profile in Chinese patients with ABC in the real‐world. The efficacy and safety profile were consistent with those reported in previous randomized phase 3 trials.

show abstract

Section: Discussionmentioning

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes

Chen,

Yan,

Luo

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Whereas, the addition of anlotinib did not increase the incidence of all grades of AEs, including grade 3–4 AEs. 15 Several clinical studies have also demonstrated that the combination of anlotinib and chemotherapy can be highly effective in the treatment of metastatic breast cancer while exhibiting acceptable toxicity. 16 , 17 The most common treatment-related adverse events (TRAEs) of anlotinib are hypertension (67.7%), fatigue (52.0%), thyroid-stimulating hormone elevation (46.6%), hypertriglyceridemia (44.6%), hand-foot syndrome (43.9%), and hypercholesterolemia (41.8%).…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial

Liang,

Liu,

et al. 2024

eClinicalMedicine

View full text Add to dashboard Cite

Exploiting a tumor softening targeted bomb for mechanical gene therapy of chemoresistant Triple-Negative breast cancer

Shen,

Guan,

et al. 2024

Chemical Engineering Journal

View full text Add to dashboard Cite

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer

Cited by 6 publications

References 36 publications

Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes

Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes

Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial

Exploiting a tumor softening targeted bomb for mechanical gene therapy of chemoresistant Triple-Negative breast cancer

Contact Info

Product

Resources

About